HSBC Holdings’s Haemonetics HAE Stock Holding History

HSBC Holdings’s Portfolio HAE Stock Details HAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-10,300	Closed	-$496K	–	3026
2025 Q3	$496K	Hold	10,300	–	–	﹤0.01%	2108
2025 Q2	$767K	Hold	10,300	–	–	﹤0.01%	1939
2025 Q1	$652K	Buy	10,300 +300	+3%	+$20.4K	﹤0.01%	1949
2024 Q4	$781K	Sell	10,000 -40,000	-80%	-$3.21M	﹤0.01%	1933
2024 Q3	$3.98M	Sell	50,000 -35,200	-41%	-$2.84M	﹤0.01%	1188
2024 Q2	$7.01M	Buy	85,200 +79,700	+1,449%	+$7.01M	﹤0.01%	958
2024 Q1	$469K	Sell	5,500 -24,900	-82%	-$1.95M	﹤0.01%	2135
2023 Q4	$2.62M	Sell	30,400 -67,800	-69%	-$5.86M	﹤0.01%	1381
2023 Q3	$8.93M	Buy	98,200 +48,200	+96%	+$4.3M	0.01%	862
2023 Q2	$4.28M	Hold	50,000	–	–	﹤0.01%	1119
2023 Q1	$4.12M	Buy	50,000 +40,200	+410%	+$3.25M	﹤0.01%	1190
2022 Q4	$763K	Buy	9,800 +9,700	+9,700%	+$780K	﹤0.01%	2100
2022 Q3	$7K	Buy	+100	New	+$7.18K	﹤0.01%	2889

Other funds holding HAE

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

RRAM

River Road Asset Management Louisville, Kentucky $8.99B AUM 12.83% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

HSBC Holdings's HAE Position: Q1 2026 in Review

HSBC Holdings increased its Haemonetics (HAE) stake by 240% in Q1 2026, buying an estimated $1.71M and bringing the position to 37,256 shares worth $2.1M. The position accounts for ﹤0.01% of the portfolio, ranked #1503.

HSBC Holdings first reported a position in HAE in Q4 2016 and has held it in 31 quarters since. The position peaked at $22.8M in Q2 2018. 324 funds tracked by Wall St. Rank hold HAE as of Q1 2026.

HSBC Holdings held 37,256 shares of Haemonetics worth $2.1M as of Q1 2026.
HSBC Holdings bought 26,284 Haemonetics shares in Q1 2026, an estimated $1.71M.
Haemonetics made up ﹤0.01% of HSBC Holdings's portfolio in Q1 2026, its #1503 holding.
HSBC Holdings first reported a position in Haemonetics in Q4 2016 and has held it in 31 quarters since.
HSBC Holdings's Haemonetics position peaked at $22.8M in Q2 2018.
324 funds tracked by Wall St. Rank held Haemonetics as of Q1 2026.

Based on HSBC Holdings's 13F filing for Q1 2026, filed 30 Apr 2026.